0 111

Cited 0 times in

Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage

Authors
 Yeon Seok Seo  ;  Soo Young Park  ;  Moon Young Kim  ;  Ju Hyun Kim  ;  Jun Yong Park  ;  Hyung Joon Yim  ;  Byoung Kuk Jang  ;  Hong Soo Kim  ;  Taeho Hahn  ;  Byung Ik Kim  ;  Jeong Heo  ;  Hyonggin An  ;  Won Young Tak  ;  Soon Koo Baik  ;  Kwang Hyub Han  ;  Jae Seok Hwang  ;  Sang Hoon Park  ;  Mong Cho  ;  Soon Ho Um 
Citation
 HEPATOLOGY, Vol.60(3) : 954-963, 2014-09 
Journal Title
 HEPATOLOGY 
ISSN
 0270-9139 
Issue Date
2014-09
MeSH
Acute Disease ; Adult ; Endoscopy, Gastrointestinal ; Esophageal and Gastric Varices / complications ; Esophageal and Gastric Varices / drug therapy* ; Female ; Gastrointestinal Hemorrhage / drug therapy* ; Gastrointestinal Hemorrhage / etiology ; Hemostasis / drug effects ; Hemostasis / physiology ; Humans ; Lypressin / analogs & derivatives* ; Lypressin / therapeutic use ; Male ; Middle Aged ; Octreotide / therapeutic use* ; Prospective Studies ; Somatostatin / therapeutic use* ; Terlipressin ; Treatment Failure ; Vasoconstrictor Agents / therapeutic use*
Abstract
Vasoactive drugs are recommended to be started as soon as possible in suspected variceal bleeding, even before diagnostic endoscopy. However, it is still unclear whether the therapeutic efficacies of the various vasoactive drugs used are comparable. The aim of this prospective, multicenter, randomized, noninferiority trial was to characterize the effects of terlipressin, somatostatin, and octreotide when they are initiated before endoscopic treatment in patients with acute variceal bleeding. Patients with liver cirrhosis and significant upper gastrointestinal bleeding were randomly assigned to receive early administration of terlipressin, somatostatin, or octreotide, followed by endoscopic treatment. Patients with nonvariceal bleeding were excluded after endoscopy. The primary endpoint was 5-day treatment success, defined as control of bleeding without rescue treatment, rebleeding, or mortality, with a noninferiority margin of 0.1. In total, 780 patients with variceal bleeding were enrolled: 261 in the terlipressin group; 259 in the somatostatin group; and 260 in the octreotide group. At the time of initial endoscopy, active bleeding was noted in 43.7%, 44.4%, and 43.5% of these patients, respectively (P=0.748), and treatment success was achieved by day 5 in 86.2%, 83.4%, and 83.8% (P=0.636), with similar rates of control of bleeding without rescue treatment (89.7%, 87.6%, and 88.1%; P=0.752), rebleeding (3.4%, 4.8%, and 4.4%; P=0.739), or mortality (8.0%, 8.9%, and 8.8%; P=0.929). The absolute values of the lower bound of confidence intervals for terlipressin versus somatostatin, terlilpressin versus octreotide, and octreotide versus somatostatin were 0.095, 0.090, and 0.065, respectively. Conclusion: Hemostatic effects and safety did not differ significantly between terlipressin, somatostatin, and octreotide as adjuvants to endoscopic treatment in patients with acute gastroesophageal variceal bleeding.
Full Text
https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.27006
DOI
10.1002/hep.27006
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Park, Jun Yong(박준용) ORCID logo https://orcid.org/0000-0001-6324-2224
Han, Kwang-Hyub(한광협) ORCID logo https://orcid.org/0000-0003-3960-6539
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/178472
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links